Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 8/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.63 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.63 |
| ▸ | CDC25B | P30305 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 4/20 | 0.51 |
| ▸ | ACHE | P22303 | 4/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19862616 | 0.89 | HSD11B1 (0.51) | F10PTPN1PTPN2CDC25BL3MBTL1 | |
| SCHEMBL2030356 | 0.78 | F10 (0.70) | F10PTPN1PTPN2CDC25BL3MBTL1 | |
| Isosteviol SCHEMBL14925190 | 0.77 | F10 (1.00) | F10PTPN1PTPN2CDC25BL3MBTL1 | |
| Isosteviol SCHEMBL22922207 | 0.77 | F10 (1.00) | F10PTPN1PTPN2CDC25BL3MBTL1 | |
| Isosteviol SCHEMBL439433 | 0.77 | F10 (1.00) | F10PTPN1PTPN2CDC25BL3MBTL1 | |
| Isosteviol SCHEMBL2987296 | 0.77 | F10 (1.00) | F10PTPN1PTPN2CDC25BL3MBTL1 | |
| Isosteviol SCHEMBL13401807 | 0.77 | F10 (1.00) | F10PTPN1PTPN2CDC25BL3MBTL1 | |
| Isosteviol SCHEMBL2025230 | 0.77 | F10 (1.00) | F10PTPN1PTPN2CDC25BL3MBTL1 | |
| Isosteviol SCHEMBL3489810 | 0.77 | F10 (1.00) | F10PTPN1PTPN2CDC25BL3MBTL1 | |
| Isosteviol SCHEMBL26990273 | 0.77 | F10 (1.00) | F10PTPN1PTPN2CDC25BL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180042874-A1 | METHOD FOR TREATING OSTEOPOROSIS | CHINA MEDICAL UNIVERSITY (TW) | 2018-02-15 | — | — | US | disclosed |
| US-20180042874-A1 | METHOD FOR TREATING OSTEOPOROSIS | CHINA MEDICAL UNIVERSITY (TW) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180042874-A1 | METHOD FOR TREATING OSTEOPOROSIS | SOST, PTH1R, CYP24A1 | F10 2201/4885PTPN1 2539/4885PTPN2 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.